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Introduction
During assisted reproductive technology (ART) treat-
ment, the use of gonadotropin-releasing hormone
(GnRH) agonists and the aspiration of follicular fluid
can lead to a relative progesterone deficit and inappro-
priate preparation of the endometrium for embryo
implantation. Supplementation of progesterone or hu-
man chorionic gonadotropin (hCG) in the luteal phases
after in vitro fertilization (IVF) cycles significantly im-
proves fertility outcomes compared with no treatment.1
No significant difference has been found between hCG
and progesterone in terms of pregnancy or miscarriage
rates, but the odds of ovarian hyperstimulation syn-
drome (OHSS) are more than 2-fold higher with
treatment involving hCG.2
Progesterone can be administered by oral, intramus-
cular or vaginal routes, but the optimal route has not
yet been established. Although there is increasing evi-
dence that vaginal and intramuscular progesterone are
at least equally effective in IVF treatment outcomes,3,4
lower clinical pregnancy and delivery rates when
using vaginal progesterone rather than intramuscular
progesterone-in-oil has been reported in a meta-analysis
of randomized trials.5 However, through the use of vag-
inal progesterone, painful application of intramuscular
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injections and their complications, such as local sore-
ness, abscesses, and inflammatory reactions, were
avoided.6
High serum estradiol levels achieved through
ovarian hyperstimulation have been claimed to reduce
endometrial receptivity,7 and progesterone has been
found to improve implantation by regulating the im-
mune response.8 Vaginal gel can produce significantly
higher endometrial progesterone levels than intramus-
cular injection, and vaginal progesterone gel is used
twice daily rather than once daily. The purpose of this
study was to compare the efficacy of these 2 forms of
luteal phase support during IVF and intracytoplasmic
sperm injection (ICSI) cycles, with ongoing pregnancy
rate as the primary outcome.
Methods
This retrospective study was approved by the Institu-
tional Ethics Review Board of National Taiwan Uni-
versity Hospital. All patients recruited in this study
underwent complete infertility evaluation, including
early follicular phase serum follicle-stimulating hor-
mone (FSH), luteinizing hormone (LH) and estra-
diol levels. Controlled ovarian hyperstimulation was
performed using the long GnRH agonist protocol.
Buserelin nasal spray (Supremon, Hoechst, Frankfurt
am Main, Germany), 200 µg four times daily, was ad-
ministered 7 days before the estimated start of the next
menses. After downregulation was achieved (menstrual
bleeding occurred and serum estradiol < 50 pg/mL),
the dose of buserelin was halved (100 µg four times
daily) and ovarian stimulation was commenced the next
day with a daily subcutaneous dose of 200 IU recombi-
nant FSH (Puregon; Organon, Oss, The Netherlands).
After giving 4 days of recombinant FSH, transvaginal
ultrasonography and serum hormone analysis (estra-
diol, progesterone, LH) were performed every other
day, and the dose of recombinant FSH was adjusted
according to the ovarian response.
When at least 2 follicles had reached a diameter of
18 mm or more, buserelin nasal spray and recombi-
nant FSH were stopped and a single bolus of 10,000IU
hCG (Profasi; Serono, Geneva, Switzerland) was ad-
ministered intramuscularly. Ultrasound-guided trans-
vaginal oocyte retrieval was then performed 34–36
hours after hCG administration. Subsequently, IVF or
ICSI was performed. Embryo transfer was done on day
3 after oocyte retrieval. According to the guidelines of
the Taiwan Society for Reproductive Medicine, no more
than 3 embryos could be transferred to women < 35
years of age, and no more than 4 embryos to women
aged ≥ 35 years. Luteal support commenced 2 days
after oocyte retrieval.
We analyzed all the fresh IVF or ICSI cycles con-
ducted by 2 attending physicians of National Taiwan
University Hospital from September 2005 to April
2007. These 2 doctors had different luteal support
protocols: one used oral estradiol valerate (Estrade;
Synmosa, Taipei, Taiwan) 6 mg twice daily combined
with vaginal progesterone gel (Crinone 8%; Fleet Labo-
ratories, Watford, UK) 90 mg twice daily, and the other
used estradiol valerate 6 mg twice daily with intra-
muscular progesterone-in-oil (Progesterone; Tai Yu,
Hsinchu, Taiwan) 50 mg daily. In total, there were 67
IVF or ICSI cycles using Crinone and 77 cycles using
intramuscular progesterone in this study.
Mid-luteal serum progesterone levels were obtained
9 days after oocyte retrieval. Serum hCG levels were
checked 16 days after oocyte retrieval, and a level above
50 IU/L was considered positive. Ultrasound exami-
nation was performed 1 week later to confirm clinical
pregnancy and determine the number of intrauterine
gestational sacs. The implantation rate was defined as
the ratio of the number of gestational sacs to the num-
ber of embryos transferred. The presence of at least 1
viable fetus at 12 weeks of gestation was classified as
ongoing pregnancy. Serum FSH, LH, estradiol and
progesterone levels were measured by means of chemi-
luminescence immunoassay (Immulite 2000; DPC,
Flanders, NJ, USA). Patients’ serum samples were
assayed immediately upon sample acquisition.
The 2 progesterone supplementation protocols
were retrospectively compared for implantation rate,
clinical pregnancy rate and ongoing pregnancy rate.
Mid-luteal serum progesterone levels were compared
between clinically pregnant and non-pregnant patients.
Ongoing pregnancy and implantation rates between
high (≥5,000pg/mL) and low (<5,000pg/mL) serum
estradiol levels on the day of hCG administration were
also analyzed. All data were analyzed using the com-
mercially available software package SPSS version 11.0
(SPSS Inc., Chicago, IL, USA) and presented as mean±
standard deviation or number (%). Statistical analysis
was carried out using Mann-Whitney U test for contin-
uous data and χ2 test for categorical data. Differences
were considered to be significant when p < 0.05.
Results
The demographic data and treatment outcomes of the
2 luteal support protocols are shown in Table 1. There
were no significant differences between the protocols
in terms of age distribution, infertility causes, baseline
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hormone levels, dosage of recombinant FSH, serum
estradiol and progesterone levels on the day of hCG ad-
ministration, number of oocytes retrieved, number of
oocytes fertilized, or number of embryos transferred.
Mid-luteal serum progesterone levels were signifi-
cantly lower (13.8 ± 5.9 vs. 41.1 ± 56.5 ng/mL, p <
0.001) in the patients using vaginal progesterone gel,
but the implantation rate (32.5% vs. 18.5%, p = 0.001),
clinical pregnancy rate (56.7% vs. 35.1%, p = 0.009)
and ongoing pregnancy rate (55.2% vs. 32.5%, p =
0.006) were all significantly higher in this group. There
were 4 triplet and 13 twin pregnancies in the vaginal
gel group, and 2 triplet and 7 twin pregnancies in the
intramuscular progesterone group. In each protocol,
there was 1 patient who suffered from moderate/
severe OHSS, and both patients recovered smoothly
after inpatient supportive care.
In each protocol, the mid-luteal serum progesterone
levels were similar between patients with and without
clinical pregnancy (Table 2). For patients with high
(≥ 5,000 pg/mL) serum estradiol levels on the day 
of hCG administration, vaginal progesterone gel still
resulted in better ongoing pregnancy and implantation
rates (Table 3). There was no significant difference in
ongoing pregnancy and implantation rates between
patients with high and low serum estradiol levels in the
vaginal gel group and in the intramuscular progesterone
group.
Discussion
In this retrospective study, we compared 2 protocols
of luteal support and found that Crinone 8% (90 mg)
Table 1. Demographic data and treatment outcomes of both luteal support protocols*
Vaginal gel (n = 67) Intramuscular (n = 77) p
Age (yr) 32.5 ± 4.0 33.5 ± 3.4 0.156
> 35 25 (37) 34 (44) 0.405
> 38 4 (6) 6 (8) 0.668
Cause of infertility 0.399
Tubal factor 10 (15) 20 (26)
Endometriosis 7 (10) 9 (12)
Male factor 40 (60) 38 (49)
Unexplained infertility 10 (15) 10 (13)
Baseline hormone levels
FSH (U/L) 6.17 ± 1.97 6.36 ± 2.12 0.702
Luteinizing hormone (U/L) 4.51 ± 2.23 4.76 ± 3.01 0.981
Estradiol (pg/mL) 32.7 ± 17.0 31.5 ± 12.8 0.918
Hormone levels on day of hCG
Estradiol (pg/mL) 4,380 ± 2,123 4,404 ± 2,056 0.949
Progesterone (ng/mL) 1.10 ± 0.55 1.29 ± 0.69 0.070
Total dose of r-FSH (IU) 1515 ± 443 1671 ± 720 0.114
Retrieved oocytes 21.3 ± 6.3 20.7 ± 7.0 0.503
Fertilized oocytes 14.0 ± 5.4 13.6 ± 5.5 0.403
Transferred embryos 2.90 ± 0.47 2.95 ± 0.48 0.401
Mid-luteal serum progesterone (ng/mL) 13.8 ± 5.9 41.1 ± 56.5 < 0.001
Implantation rate 63/194 (32.5) 42/227 (18.5) 0.001
Clinical pregnancies 38 (56.7) 27 (35.1) 0.009
Ongoing pregnancies 37 (55.2) 25 (32.5) 0.006
*Data presented as mean ± standard deviation or n (%). FSH = follicle-stimulating hormone; hCG = human chorionic gonadotropin; r-FSH = recombinant FSH.
Table 2. Mid-luteal serum progesterone levels in clinically pregnant
and non-pregnant patients
Pregnant Non-pregnant p
Vaginal gel n = 38 n = 29
Progesterone 14.4 ± 6.0 13.1 ± 5.9 0.386
(ng/mL)
Intramuscular n = 27 n = 50
Progesterone 36.1 ± 32.6 43.8 ± 66.3 0.580
(ng/mL)
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twice daily resulted in higher ongoing pregnancy rates
than intramuscular progesterone 50 mg daily.
Normal luteal function is essential for maintaining
first-trimester pregnancy, but corpora lutea may be com-
promised during controlled ovarian hyperstimulation
or oocyte retrieval. Luteal support in IVF/ICSI cycles
with progesterone or hCG is a standard procedure to
improve pregnancy outcomes, but hCG increases the
odds of OHSS, a relatively common and potentially
life-threatening complication of ovarian stimulation.
When using hCG for luteal support, our experience
shows that the overall frequency of severe OHSS is
5.5%.9 Although luteal supplementation with proges-
terone could not eradicate OHSS, the risk was markedly
decreased to 1.4% (2/144) in the present study.
The pharmacokinetic profiles of vaginal and intra-
muscular progesterone administration are extremely
different: intramuscular injection produces high plasma
levels and low endometrial levels, but the opposite oc-
curs with vaginal gel application.10–12 Historically, luteal
adequacy was judged by the measurement of serum
progesterone concentrations, but we did not find any
significant difference in mid-luteal progesterone levels
between pregnant and non-pregnant patients.
Despite low serum progesterone levels with vagi-
nal administration, the substantial local effect may
induce full secretory transformation of the endome-
trial stroma.13 But some studies reported that using
vaginal progesterone gel compared with intramuscular
progesterone-in-oil resulted in higher rates of biochem-
ical pregnancy loss,14 lower implantation rates,15–17
and lower ongoing pregnancy rates.18 The definite
explanation is not clear, but lower serum proges-
terone levels when using vaginal gel may lead to a
higher systemic estradiol-to-progesterone ratio, and
decreased implantation efficiency in this setting has
been reported.19
Most previous studies used Crinone 90 mg vaginal
progesterone gel daily, not 90 mg twice daily. The
higher frequency of vaginal progesterone gel might
compensate for the effect of high systemic estradiol-to-
progesterone ratio and also maintain normal endome-
trial histology. In a study evaluating oocyte donation
model,20 Crinone 90 mg twice daily achieved com-
parable ongoing pregnancy rates to intramuscular pro-
gesterone administration. In that study, all adequate
endometrial biopsy specimens from patients using
Crinone were in phase.
Extremely high serum estradiol levels achieved
through ART cycles have been claimed to cause lower
pregnancy rates by having adverse effects on endome-
trial receptivity.7,21–23 Extraordinarily high serum estra-
diol levels (≥ 5,000 pg/mL) are associated with severe
downregulation of the expression of endometrial prog-
esterone receptors,24 asynchronous endometrial devel-
opment,25 and suboptimal endometrial perfusion.26
High serum estradiol concentrations may also reduce
endometrial expression of T helper type 2 (Th2) cy-
tokines such as interleukin-11 and interleukin-6,27 and
there is evidence to show that pregnancy rejection is
mediated by T helper type 1 (Th1) cytokines, whereas
Th2 cytokines play an important role in sustaining
pregnancy.28
Progesterone has been found to specifically block
Th1 immunity to trophoblasts,8 therefore high local
progesterone concentrations from vaginal gel might
decrease the detrimental effect of high systemic estra-
diol levels. We used 5,000 pg/mL as the cut-off value
of serum estradiol levels on the day of hCG adminis-
tration and compared the ongoing pregnancy and im-
plantation rates. At both high and low estradiol levels,
the vaginal gel group still had better ongoing pregnancy
and implantation rates, but the difference in ongoing
pregnancy rates was marginally significant (54.8% vs.
34.7%, p = 0.055) for patients with low estradiol levels.
In the intramuscular progesterone group, although
without statistical significance, there were differences
of more than 6% in absolute terms in both ongoing
Table 3. Ongoing pregnancy rates and implantation rates with different serum estradiol levels on the day of human chorionic
gonadotropin administration
Serum estradiol ≥ 5,000 pg/mL Serum estradiol < 5,000 pg/mL p
Ongoing pregnancy rate
Vaginal gel 14/25 (56%) 23/42 (54.8%) 0.921
Intramuscular 8/28 (28.6%) 17/49 (34.7%) 0.581
p 0.043 0.055
Implantation rate
Vaginal gel 24/73 (32.9%) 39/121 (32.2%) 0.926
Intramuscular 11/80 (13.8%) 31/147 (21.1%) 0.174
p 0.005 0.039
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pregnancy rates (28.6% vs. 34.7%, p = 0.581) and
implantation rates (13.8% vs. 21.1%, p = 0.174) in favor
of low over high serum estradiol levels.
In the mid-luteal phase of IVF–embryo transfer
cycles without hormone supplementation, serum estra-
diol and progesterone often decrease to low levels.29
Subnormal mid-luteal estradiol concentrations have
been associated with endometrial maturation delay and
reduced endometrial receptivity.30 Estrogen supple-
mentation can result in a significant elevation of serum
estradiol levels, and the addition of estrogen to prog-
esterone supplementation in the luteal phase can sig-
nificantly improve pregnancy and implantation rates
in patients treated with the long GnRH agonist pro-
tocol.31,32 Accordingly, we gave estrogen as part of
luteal phase support for all patients after controlled
ovarian hyperstimulation.
In conclusion, adequate tissue level of progesterone
can be obtained after the vaginal administration of
progesterone gel, and luteal adequacy should not be
judged only by serum progesterone concentrations.
Compared with intramuscular progesterone-in-oil,
Crinone 8%, 90 mg twice daily significantly improves
pregnancy outcomes. Vaginal gel might also improve
endometrial receptivity under extraordinarily high
serum estradiol levels. Although significant limitations
of a retrospective analysis exist, the patient-specific
characteristics of the 2 groups were generally similar.
More prospective randomized trials are needed to
find the best route of luteal supplementation in ART
treatment.
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